


PRODUCT INFORMATION



BayCysLT₂
Item No. 10532

CAS Registry No.: 712313-33-2
Formal Name: 3-[[[3-(3-carboxycyclohexyl)amino]carbonyl]-4-[3-[4-(4-phenoxybutoxy)phenyl]propoxy]-benzoic acid
Synonym: CAY10633
MF: C₃₄H₃₉NO₈
FW: 589.7
Purity: ≥95%
UV/Vis.: λ_{max}: 220 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BayCysLT₂ is supplied as a crystalline solid. A stock solution may be made by dissolving the BayCysLT₂ in the solvent of choice, which should be purged with an inert gas. BayCysLT₂ is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of BayCysLT₂ in these solvents is approximately 20 mg/ml.

BayCysLT₂ is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BayCysLT₂ should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BayCysLT₂ has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BayCysLT₂ is a cysteinyl leukotriene 2 (CysLT₂) receptor antagonist (IC₅₀ = 53 nM).¹ It selectively inhibits calcium mobilization induced by leukotriene D₄ (LTD₄; Item No. 20310) in HEK293 cells expressing human CysLT₂ receptors over HEK293 cells expressing CysLT₁ receptors when used at a concentration of 100 nM. BayCysLT₂ reverses LTC₄-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated perfused guinea pig hearts.² *In vivo*, BayCysLT₂ (3 mg/kg) reduces infarct volume in a human CysLT₂ receptor transgenic mouse model of myocardial ischemia and reperfusion injury induced by left anterior descending coronary artery (LAD) ligation.¹

References

1. Ni, N.C., Yan, D., Ballantyne, L.L., *et al.* A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. *J. Pharmacol. Exp. Ther.* **339**(3), 768-778 (2011).
2. Harter, M., Erguden, J., Wunder, F., *et al.* Isophtalic acid derivatives. *Bayer Pharma AG.* **US20060154912A1**, (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/31/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM